Winship Cancer Institute of Emory University | Strategic Alliance Partners

October 13, 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

October 12, 2023

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

October 12, 2023

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

October 06, 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

October 06, 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

October 06, 2023

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and sheds light on the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment of this patient population.

October 04, 2023

Madhav V. Dhodapkar, MBBS, discusses efficacy and safety findings from the dose-expansion portion of the phase 2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

October 03, 2023

Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.

September 29, 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

September 29, 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

September 21, 2023

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

September 12, 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

September 11, 2023

Anthony M Hunter, MD, discusses the current treatment landscape with JAK inhibitors in myelofibrosis.

June 20, 2023

Nabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

June 04, 2023

Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.

May 29, 2023

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

May 23, 2023

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

May 22, 2023

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.

May 22, 2023

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

May 15, 2023

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.